U.S. markets closed

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0300+0.0500 (+5.10%)
At close: 04:00PM EDT
1.0300 0.00 (0.00%)
After hours: 07:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.9800
Bid1.0000 x 800
Ask1.0300 x 1100
Day's Range0.9720 - 1.0400
52 Week Range0.9580 - 6.4000
Avg. Volume390,363
Market Cap43.17M
Beta (5Y Monthly)3.40
PE Ratio (TTM)N/A
EPS (TTM)-1.7470
Earnings DateAug 01, 2022 - Aug 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AQST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aquestive Therapeutics, Inc.
    Technical Assessment: Neutral in the Intermediate-TermWe are raising our intermediate-term technical outlook to neutral from bearish. This reverses our April 22 intermediate-term downgrade from neutral to bearish. This action is not a green light and we are not saying the bottom is in and it's up, up, and away from here. But we do think the major indices are attempting to hammer out (via a candlestick pattern) a bottom because we have seen a few "sticks" in recent trading sessions. Simply put, we are seeing days where stocks trade significantly lower but then finish strong.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Aquestive Therapeutics Announces CEO Transition

    Daniel Barber, current Chief Operating Officer of Aquestive, appointed as President and Chief Executive Officer and member of Board of DirectorsKeith Kendall, President and Chief Executive Officer and member of Board of Directors, will be leaving the CompanyKeith Kendall engaged as consultant to end of year to assist in management transition WARREN, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’

  • Simply Wall St.

    When Will Aquestive Therapeutics, Inc. (NASDAQ:AQST) Become Profitable?

    We feel now is a pretty good time to analyse Aquestive Therapeutics, Inc.'s ( NASDAQ:AQST ) business as it appears the...

  • GlobeNewswire

    Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference

    WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the H.C. Wainwright Global Investment Conference from May 23rd to May 26th. The Aquestive team is scheduled to present on May 25th at 2:30 pm ET and will host investor meetings at the